• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Primary Prevention of CVD with Aspirin: Benefits vs Risks
J Fam Pract. 2021 Jul;70(6S):S41-S46. doi: 10.12788/jfp.0222.ABSTRACTLow-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg/d) is widely used in the prevention of cardiovascular (CV) events based on the results of large-scale studies supporting a benefit. However, questions remain regarding the benefit-risk relationship in certain settings since long-term use of ASA is not devoid of risk. Incontrovertible evidence supports the benefits of ASA treatment, which exceed the risks, in patients who have had a previous CV event (myocardial infarction, stroke, unstable angina, or transient ischemic attack). Nonetheless, the qu...
Source: The Journal of Family Practice - August 25, 2021 Category: Practice Management Authors: Steven M Weisman Stephen Brunton Source Type: research

Help Desk Answers: Do novel oral anticoagulants safely prevent stroke in patients with nonvalvular A-fib?
Abstract Yes. Dabigatran, rivaroxaban, and apixaban are safe and effective compared with warfarin for preventing stroke in patients with nonvalvular atrial fibrillation. These novel oral anticoagulants (NOACs) are noninferior in reducing the number of strokes and systemic emboli and in lowering all-cause mortality while not increasing major bleeding complications and hemorrhagic events. PMID: 27474824 [PubMed - as supplied by publisher]
Source: The Journal of Family Practice - May 31, 2016 Category: Practice Management Authors: Siewert R, Hostetter J Tags: J Fam Pract Source Type: research

Pages: 1  2  3  4  5